Table 1.
Numerical CIN: results and patient group characteristics
| Healthy control subjects N= 10 | Lymphoma patients N= 7 | Patients with MDS N= 18 | Patients with secondary AML N= 14 | Patients with de novo AML N= 16 | |
|---|---|---|---|---|---|
| Female sex | 0/10 | 2/7 | 8/18 | 4/14 | 6/16 |
| Age (years) | |||||
| Median | 35 | 60 | 69 | 68.5 | 56.5 |
| Range | 0−73 | 40−68 | 42−85 | 37−74 | 23−81 |
| nCIN (%) | |||||
| Mean ± SD | 6.0 ± 1.5 | 6.0 ± 1.1 | 7.0 ± 2.5 | 9.0 ± 12.2 | 5.9 ± 1.7 |
| Median | 6.0 | 5.8 | 6.9 | 5.6 | 6.0 |
| Range | 3.8−7.9 | 4.2−7.7 | 3.8−13.5 | 2.7−49.6 | 3.5−9.2 |
| P-value | − | 0.98 | 0.17 | 0.38 | 0.89 |
MDS: myelodysplastic syndrome; AML: acute myeloid leukaemia; nCIN: numerical chromosomal instability; SD: standard deviation. P-values are given relative to the group of healthy control subjects.